SPI1 and Alzheimer disease: Combined results of these analyses suggested Vorinostat or other HDAC inhibitors that knockdown PU.1 expression may be useful as potential therapies that could reduce microglial-mediated immune responses, such as the excess inflammation observed in AD (Rustenhoven et al., 2018; Smyth et al., 2018).